Get started
SanofiSanofiSanofi

Sanofi

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

SNYNF trade ideas

SNY Fib Levels On The Radar & WhySNY and TBIO buttoned up the news this morning sending a bunch of other biotech stocks running higher. Now that this is out of the way, levels could be important for longs looking for "what's next" and the 236 Fib level seems to be that area to watch. It was an area that the volatile SNY stock settled above for weeks and now is an area it hasn't been able to break above for the last several weeks. Heading into the month after this acquisition, it's gonna be interesting to see if mRNA stocks start to catch a bit more. " A mega buyout from Sanofi (NASDAQ: SNY) has investors looking at biotech stocks today. If you remember our article, “Top Biotech Penny Stocks On Robinhood To Watch This Week,” we discussed Sanofi and its strengthening relationship with a former penny stock, Translate Bio Inc. (NASDAQ: TBIO)...Sanofi had previously pledged to invest 400 million euros annually in a vaccines R&D facility to advance mRNA vaccines with Translate to benefit. Tuesday, Sanofi formally announced a $3.2 billion buyout of its vaccine collaboration partner. This was at $38 a share in cash, roughly 30% higher than the close on August 2nd. " Quote Source & Read More: Hot Biotech Stocks To Watch After Sanofi’s Acquisition Of Translate Bio
NASDAQ:SNY
by PennyStocks101
Sanofi - bullish continuation confirmed on 4HSanofi S.A. is a French multinational pharmaceutical company headquartered in Paris, France, as of 2013 the world's fifth-largest by prescription sales. Shown here is the daily chart, with monthly zones/lines of support (green dashed lines) and resistance (red dashed lines). Also shown is a Fibonacci drawn on the monthly chart. In the 4H, Sanofi is clearly bullish ( recent breakout of green Heikin Ashi candles, price above the 50 and 200 MA, recent cross over of 50/200 MA on 4H, and an RSI > 50. Price recently dipped a bit to the downside, but recovered, and is in the 23.8% Fibonacci zone, to which it has returned. On the daily chart, price is between the 50-day MA and 200-day MA, which appears to be crossing over soon. This would be a bullish signal on Daily chart if it happens. If price does move upward, the there are several levels of resistance (monthly), namely at around 83.57, 86.33, 92.94. 95.86 and the all time high of 101.06. A price drop down to 79.00/80.00 would invalidate the bullish signal. Keen to know what others think. Please leave a comment or link to your own ideas! Charts are for information purposes only. Not trade suggestions. DYOR (Do your own research) - act responsibly with your money.
EURONEXT:SANLong
by BradtNom
Sanofi consolidates, new bullish trend in 2022I expect the price of Sanofi to carry on falling inside the descending channel, especially if global market consolidates due to rising inflation fears. Sanofi has not been able to produce a covid vaccine and is just starting phase I/II trials for a second vaccine candidate which leaves the near future a bit blurry and may keep investors away. Once the price has reached the bottom of the horizontal range (64 EUR) I expect a reversal for a new bullish trend towards 95EUR by end of 2022.
EURONEXT:SAN
by Jeff_Trad
Cup and HandleNo rising wedges noted and is close to B/O (breakout) Stop can be below handle low or melow mid cup Everyone has a different tolerance on stops. I think it is imperative to have a goal in mind before you place a trade. I am working on trying to focus on just a few trades at a time as I have an issue with wanting to buy everything! LOL I end up with smaller positions in too many stocks verses weeding through and picking just a few I think are the best and placing more money in those. We all have improvements we can make. Making a mistake is not the end of the world as long as we do not repeat it over and over. Not a recommendation
NASDAQ:SNYLong
by lauralea
Sanofi, leading in the fight for COVID-19Sanofi is leading the clinical development and registration of the COVID-19 vaccine and expects a Phase 1/ 2 study to start in September, followed by a Phase 3 study by the end of 2020. If data are positive, regulatory approval could be achieved by the first half of 2021. In parallel, Sanofi and GSK are scaling up manufacturing of the antigen and adjuvant to produce up to one billion doses per year overall. Sanofi and GSK are committed to making the vaccine available globally As we are hitting the golden zone in FIB retrace. Im going to put this on watch.
EURONEXT:SAN
by Wteres